Regeneron Pharmaceuticals (REGN)
Nasdaq · Tarrytown, New York, USA · Founded 1988 · CEO Leonard Schleifer
Valuation summary
$1,086.97 fair value versus $923.34 in the market, a difference of +17.7%. Rated Buy.
| Fair value per share | $1,086.97 |
| Current share price | $923.34 |
| Upside / downside | +17.7% |
| Bear case | $792.18 |
| Bull case | $1,496.62 |
| Discount rate (WACC) | 9.6% |
| Terminal growth | 2.80% |
| Market capitalisation | $96B |
| EV / Sales | 5.0x |
About Regeneron Pharmaceuticals
Founded in 1988 by Leonard Schleifer, a neurologist, with George Yancopoulos as chief scientist — both still run the company from Tarrytown, New York. Regeneron's platform technologies, VelocImmune and VelociSuite, generate fully human antibodies quickly and have produced an unusual hit rate. Key products: Eylea for retinal disease, Dupixent for atopic dermatitis and asthma, which is co-developed with Sanofi and is one of the fastest-growing drugs in the world, and Libtayo in oncology. It also runs a large human genetics sequencing programme.
Investment case
- Dupixent keeps adding indications and is on track to become one of the largest drugs in the industry.
- The antibody discovery platform has repeatedly produced approved medicines, a rare and hard-to-copy record, most recently Pasatru for the ultra-rare bone disease FOP in August 2026.
- Substantial net cash and no reliance on external financing.
Key risks
- Eylea faces aggressive biosimilar competition in the US, and that erosion is already visible in the numbers.
- Dupixent economics are shared with Sanofi, so Regeneron captures only part of the value, and the expanded October 2026 alliance left Dupixent terms unchanged.
- Concentration in two products means a single competitive setback moves the whole story.
Recent developments
- 2026-10-30 · Q3 revenue up 36% to $5.1bn with record Dupixent, EYLEA HD up 62% and Libtayo; non-GAAP EPS up 70% to $20.07 source
- 2026-10-01 · Expanded Sanofi alliance: $1B upfront and up to $7B milestones for four long-acting antibodies, split 50:50; Dupixent terms unchanged; shares fell 2.9%. source
- 2026-08-19 · FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, an ultra-rare disease of abnormal bone growth. source
Revenue by segment
| Dupixent collaboration revenue | 44% |
| Eylea | 32% |
| Libtayo & Other | 24% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $19.6B | $4.7B |
| Year 2 | $22.8B | $5.3B |
| Year 3 | $26.0B | $5.9B |
| Year 4 | $29.1B | $6.5B |
| Year 5 | $31.8B | $6.9B |
What the street says
Well regarded scientifically, with the debate centred on how fast Eylea erodes versus how fast Dupixent grows. The October 2026 Sanofi deal, which brings $1B upfront but no better Dupixent economics, disappointed some investors, and a securities suit over a failed melanoma trial is pending.
Comparable companies: VRTX · EW · ISRG · IDXX · ARGX · SNY · ABT · A
Open the interactive model, price chart and sensitivity grid →